Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.60 | 7.00 | -0.08% |
| CAC 40 | 8,126.33 | 43.76 | -0.54% |
| DAX 40 | 23,588.99 | 287.56 | -1.20% |
| Dow JONES (US) | 47,055.31 | 401.91 | -0.85% |
| FTSE 100 | 9,687.94 | 10.43 | -0.11% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,883.94 | 16.65 | -0.07% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,459.15 | 5.31 | -0.04% |
| S&P 500 | 6,723.72 | 10.39 | -0.15% |
| S&P/ASX 200 | 8,571.80 | 7.00 | -0.08% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |